Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease

20250 citationsJournal Articlegold Open Access

Authors

ClinicalTrials.gov, NCT06227910.

Published in: Contemporary Clinical Trials Communications

Volume 48, pp. 101574-101574

Field-Weighted Citation Impact: 0.00